Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $140.00 at BMO Capital Markets

Neurocrine Biosciences (NASDAQ:NBIX) had its target price decreased by BMO Capital Markets from $147.00 to $140.00 in a research note released on Thursday,Benzinga reports. BMO Capital Markets currently has a market perform rating on the stock.

A number of other research firms have also recently commented on NBIX. JPMorgan Chase & Co. cut their price target on shares of Neurocrine Biosciences from $179.00 to $177.00 and set an “overweight” rating on the stock in a report on Monday, January 12th. Wall Street Zen upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a report on Sunday, February 8th. Piper Sandler upped their target price on shares of Neurocrine Biosciences from $175.00 to $179.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. TD Cowen raised their target price on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Finally, UBS Group decreased their price target on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Fifteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and an average price target of $177.56.

Neurocrine Biosciences Stock Down 10.4%

Shares of Neurocrine Biosciences stock opened at $123.10 on Thursday. The stock’s fifty day moving average is $140.77 and its two-hundred day moving average is $140.46. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $160.18. The company has a market capitalization of $12.27 billion, a PE ratio of 26.42, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the completion of the sale, the chief executive officer directly owned 140,407 shares in the company, valued at approximately $18,632,008.90. This trade represents a 20.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Darin Lippoldt sold 4,376 shares of Neurocrine Biosciences stock in a transaction on Monday, December 8th. The stock was sold at an average price of $159.65, for a total transaction of $698,628.40. Following the sale, the insider owned 43,405 shares of the company’s stock, valued at $6,929,608.25. The trade was a 9.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 61,966 shares of company stock worth $8,625,166. 4.80% of the stock is currently owned by company insiders.

Institutional Trading of Neurocrine Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in NBIX. USA Financial Formulas acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth about $25,000. Geneos Wealth Management Inc. grew its holdings in Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in shares of Neurocrine Biosciences by 120.5% during the 3rd quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after acquiring an additional 100 shares during the period. Eastern Bank acquired a new stake in Neurocrine Biosciences during the third quarter worth about $27,000. Finally, DJE Kapital AG purchased a new stake in shares of Neurocrine Biosciences in the 4th quarter valued at approximately $28,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Analysts continue to show conviction in the long‑term story — several firms reiterated Buy/Outperform ratings and high price targets, signaling confidence in the Ingrezza franchise and pipeline potential. TipRanks: Bank of America reiterates Buy
• Positive Sentiment: Recent analyst upgrades/raises include Citigroup lifting its price target (to $204) and Wedbush nudging its target higher — evidence that some investors still see significant upside. Benzinga: Citi/Wedbush price target moves
• Positive Sentiment: Underlying commercial results were strong: full‑year 2025 net product sales and year‑over‑year revenue growth reinforce that Ingrezza remains a durable cash generator. PR Newswire: Q4 and FY2025 results
• Neutral Sentiment: Revenue came in roughly in line with expectations (~$805M), so top‑line growth isn’t the main driver of the decline — the market is reacting to profit/guidance details. MarketBeat: Earnings report & transcript
• Neutral Sentiment: Analyst reactions are mixed: several firms trimmed price targets modestly (RBC, BMO, Needham adjustments) while most maintained Buy/Outperform ratings — creates volatility but not a broad sell consensus. TipRanks: Mixed PT adjustments
• Negative Sentiment: EPS missed expectations — adjusted EPS reported below consensus — which, combined with cautious near‑term commentary, triggered selling pressure. MarketBeat: EPS miss details
• Negative Sentiment: Market commentary flagged “disappointing Ingrezza guidance” as a key catalyst for the decline — investors appear to have expected a stronger 2026 sales outlook. Benzinga: Analysts on Ingrezza guidance
• Negative Sentiment: Trading showed heavy volume and reports noted insider selling activity — both amplify downside momentum in the near term. QuiverQuant: Stock falls, insider selling

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.